Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 6 studies | 24% ± 5% | |
| plasma cell | 5 studies | 38% ± 10% | |
| fibroblast | 3 studies | 20% ± 1% | |
| GABAergic neuron | 3 studies | 19% ± 1% | |
| glutamatergic neuron | 3 studies | 27% ± 8% |
Insufficient scRNA-seq data for expression of TRAM2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 100% | 4968.30 | 459 / 459 | 99% | 30.79 | 1111 / 1118 |
| lung | 100% | 4969.55 | 577 / 578 | 99% | 28.28 | 1143 / 1155 |
| intestine | 100% | 4093.88 | 966 / 966 | 99% | 25.13 | 520 / 527 |
| skin | 99% | 12533.08 | 1783 / 1809 | 99% | 47.58 | 469 / 472 |
| stomach | 98% | 2509.92 | 353 / 359 | 99% | 26.98 | 284 / 286 |
| ovary | 100% | 3892.90 | 180 / 180 | 97% | 19.84 | 417 / 430 |
| prostate | 99% | 2209.80 | 242 / 245 | 97% | 17.73 | 486 / 502 |
| uterus | 100% | 4653.46 | 170 / 170 | 95% | 20.45 | 434 / 459 |
| esophagus | 95% | 2773.29 | 1379 / 1445 | 99% | 32.34 | 181 / 183 |
| thymus | 100% | 4458.30 | 652 / 653 | 94% | 19.12 | 566 / 605 |
| bladder | 100% | 4577.95 | 21 / 21 | 92% | 17.71 | 466 / 504 |
| pancreas | 88% | 1162.09 | 287 / 328 | 97% | 27.57 | 173 / 178 |
| liver | 99% | 2909.63 | 223 / 226 | 83% | 10.46 | 336 / 406 |
| kidney | 99% | 2212.28 | 88 / 89 | 79% | 15.57 | 710 / 901 |
| adrenal gland | 95% | 1609.10 | 246 / 258 | 77% | 8.66 | 176 / 230 |
| adipose | 100% | 6375.12 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 6557.39 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 25.29 | 45 / 45 |
| blood vessel | 100% | 5591.29 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| brain | 21% | 204.49 | 566 / 2642 | 78% | 10.42 | 548 / 705 |
| heart | 99% | 2236.38 | 850 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 18.76 | 77 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 21.66 | 27 / 29 |
| muscle | 40% | 434.11 | 319 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 35% | 990.73 | 323 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006616 | Biological process | SRP-dependent cotranslational protein targeting to membrane, translocation |
| GO_0032964 | Biological process | collagen biosynthetic process |
| GO_0045048 | Biological process | protein insertion into ER membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005515 | Molecular function | protein binding |
| Gene name | TRAM2 |
| Protein name | Translocation associated membrane protein 2 isoform 1 Translocation associated membrane protein 2 isoform 2 Translocating chain-associated membrane protein 2 |
| Synonyms | KIAA0057 |
| Description | FUNCTION: Necessary for collagen type I synthesis. May couple the activity of the ER Ca(2+) pump SERCA2B with the activity of the translocon. This coupling may increase the local Ca(2+) concentration at the site of collagen synthesis, and a high Ca(2+) concentration may be necessary for the function of molecular chaperones involved in collagen folding. Required for proper insertion of the first transmembrane helix N-terminus of TM4SF20 into the ER lumen, may act as a ceramide sensor for regulated alternative translocation (RAT) . . |
| Accessions | G1UI27 ENST00000182527.4 Q15035 A0A0S2Z538 A0A024RD84 |
